Screener
Zymeworks ZYME Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $4.59M-90.6% | $2.41M-91.1% | $2.52M-91.9% | $27.61M+72.6% | $48.73M+153% | ||
| $27.44M-20.4% | $34.46M-3.6% | —— | $35.58M-2.1% | $34.45M+18.1% | ||
| $19.34M+29.3% | $15.07M-11.3% | $15.43M-4.7% | $14.15M+2.1% | $14.95M-4.6% | ||
| $46.77M-5.3% | $49.53M-6.1% | $46.67M-12.4% | $49.72M-1.0% | $49.4M-20.5% | ||
| -$42.18M-6,158% | -$47.12M-84.0% | -$44.15M-98.7% | -$22.11M+35.4% | -$674K+98.4% | ||
| -919%-918pp | -1,956.7%-1,862pp | -1,755.5%-1,684pp | -80.1%+134pp | -1.4%+221pp | ||
| $3.29M-4.1% | $2.71M-20.8% | $2.98M-27.1% | $3.53M-26.2% | $3.43M-33.5% | ||
| $196K+132% | $120K+145% | -$302K-188% | $315K+254% | -$621K-645% | ||
| -$45.29M-2,225% | -$46.35M-109% | -$41.48M-133% | -$18.27M+38.3% | $2.13M+106% | ||
| -$273K-46.8% | -$2.19M-542% | —— | $1.34M+491% | -$186K-374% | ||
| -$45.02M-2,043% | -$44.16M-95.1% | -$41.21M-75.3% | -$19.6M+34.3% | $2.32M+106% | ||
| -980.8%-986pp | -1,834%-1,750pp | -1,638.5%-1,563pp | -71%+116pp | 4.8%+201pp | ||
| -$0.62-2,167% | -$0.59-96.7% | -$0.55-71.9% | -$0.26+33.3% | $0.03+106% | ||
| -$41.05M-2,359% | -$45.98M-99.8% | -$43.07M-124% | -$20.56M+36.1% | $1.82M+104% | ||
| -894.3%-898pp | -1,909.4%-1,825pp | -1,712.5%-1,651pp | -74.4%+127pp | 3.7%+217pp | ||
| -$42.18M-6,158% | -$47.12M-84.0% | -$44.15M-98.7% | -$22.11M+35.4% | -$674K+98.4% |
FAQ
- What is Zymeworks's revenue?
- Zymeworks (ZYME) generated $37.1M in revenue over the trailing twelve months, down 69.8% year over year.
- Is Zymeworks profitable?
- Zymeworks is not currently profitable: it reported a net loss of $150.0M over the trailing twelve months, a -404.0% net margin.
- What is Zymeworks's earnings per share?
- Zymeworks's diluted EPS over the trailing twelve months is $-2.02.
- Where does Zymeworks's income statement data come from?
- Every line is extracted from Zymeworks's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
